Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the effectiveness of the NatroxTM Topical Oxygen device versus a placebo in patients with non-healing leg ulceration in conjunction with standard best practice.


Clinical Trial Description

Patients will be screened for two weeks before enrollment to assess whether their ulcers are "non-healing", defined as a reduction in wound surface of < 25% after two weeks of standard best practice wound care . On enrolment and randomisation to active or placebo treatment the patient will be treated for six weeks or until 100% epithelialisation, whichever is the sooner, and then treatment will revert to standard best practice, defined as moist wound healing plus compression where appropriate. The reference ulcer will be followed up at two weeks and then at six weeks after the end of the active treatment period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01913704
Study type Interventional
Source Inotec AMD Limited
Contact
Status Withdrawn
Phase N/A
Start date October 2012
Completion date October 2014

See also
  Status Clinical Trial Phase
Completed NCT03257098 - Allogeneic ABCB5-positive Stem Cells for Treatment of CVU Phase 1/Phase 2
Terminated NCT02742844 - Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From Ulcers Phase 1/Phase 2
Terminated NCT02307448 - Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds N/A
Recruiting NCT04971161 - Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb) Phase 2